New study to test novel psychedelic compound as potential treatment for alcohol use disorder

Modern mental health company Clerkenwell Health announced today that it is working with clinical-stage biotechnology company Beckley Psytech on a Phase IIa study investigating whether a novel psychedelic compound, combined with psychological support, could be an effective treatment for alcohol use disorder (AUD).

SPOC Proteomics announces new product launch at SLAS2024

SPOC Proteomics, Inc, a deep-tech life sciences company based out of Scottsdale Arizona (HQ) and Menlo Park California, announced the commercial launch of their customizable

February 7, 2024

Bristol Myers, Ideaya tout data in solid tumors with certain genetic mutations

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 26, 2024

Lykos takes another hit as ICER lays out ‘insufficient’ evidence for MDMA-based treatment

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.